You can cancel an election and ban the winner from running (Romania), you can ban your opponents from ever running again (Hungary), you can threaten to ban the main opposition party and subject it to relentless investigations by the secret police (Germany), you can threaten a ban on the leading presidential candidate and make them wear an ankle monitor (France), every member of your circle can be investigated for corruption (Spain), you can try and cancel local elections because you will lose them (Britain), and you can storm the constitutional court with riot police because you want to control it (Poland).
You can just do all these things. The secret is you just have to be on the right side of the European Commission.
Casi 11 meses tardaron en hacerse públicos los audios clave del apagón, que revelaban graves problemas de tensión en la red. Red Eléctrica incluso se negó a entregar los suyos al Senado.
En el accidente ferroviario de Urda (Toledo), apenas 12 horas para que los audios aparecieran simultáneamente en El País, la SER y elDiario·es, poniendo a un trabajador de Adif en el punto de mira cuando la investigación apenas había comenzado.
Repugnante, indigno y miserable.
Todo mi apoyo a las víctimas, a sus familiares y amigos. Y todo mi desprecio a quienes pretendan eludir su responsabilidad en el accidente y a sus encubridores.
There has been either an inadvertent or deliberate effort in Spain to focus attention on an individual rather than on management or ministerial failures (such as the failure to complete LZB replacement on this line).
Human error is always a symptom and never a cause.
Out now in @CellCellPress: ✨SPARCS✨, a
platform for discovering the genes behind complex cellular phenotypes.
SPARCS combines Al-powered image analysis with automated laser microdissection to precisely isolate cells from large mutant libraries.
Paper and highlights👇(1/9)
I’ll be at the @scverse_team hackathon in Berlin next week. We’ll extend scPortrait (https://t.co/EEiqWnkdrr) towards agentic AI workflows and interactive vis.
Check the great projects we and others are up to: https://t.co/kY10wNySND
Looking fwd to seeing many of you there!
Huge news today at Isomorphic Labs!
We have secured $2.1 Billion investment to advance the most important mission that AI can unlock: to change the way we can improve human health and create new medicines for patients around the world.
This funding milestone was built on the strength of our AI drug design engine (IsoDDE), which has already proven its worth (aside from smashing benchmarks) by designing breakthrough new molecules and creating new scientific breakthroughs across our drug discovery programs.
Our IsoDDE is giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that we couldn’t unlock until now.
A massive thank you to our incredible team across London, Boston and Lausanne, whose relentless work made this possible, and to our partners who share our ultimate vision.
Now we have so much more to build together!
I’ve always believed the No.1 application of AI should be to improve human health.
That work started with AlphaFold, and now at @IsomorphicLabs with the mission to reimagine drug discovery and one day solve all disease!
We are turbocharging that goal with $2.1B in new funding.
Wow this is trained on 21 patients data in 1 cancer. 😬
For context we are training these types of models on almost 4,000 patients across all modalities paired.
“Our training data comprises of data collected from 21 patients across different stages of lung adenocarcinoma.”
labs will publish details on arch, optim, objectives, scaling, kernels, literally everything except data
and academia will be astounded for the hundredth time, wondering to itself where the secret sauce is
Across many labs, SCALING single cell foundation models has had mixed success.
We think the key is CONTEXT.
*Spatial* single cell RNA data preserves the natural biological context of gene expression within animal tissue — in our case, tissue from human patients.
When we train models on large, diverse spatial datasets (100M cells across a dozen cancer types) we see BIG benefits from bigger models and longer context (effectively how much patient data the models see at once.)
Interestingly, the bigger the model, the better it gets with longer context. Maybe only larger models can capture complex spatial gene expression patterns across large regions of tissue.
We think that scaling SPATIAL single cell models is the way — maybe the only way — to discover new, therapeutically actionable biology across patients and solve the CLINICAL TRANSLATION problem that plagues drug development.
Big day for @NOETIK_ai ! We're licensing our OCTO-VirtualCell models in lung and colorectal cancer to @GSK, one of pharma's best at using AI to help patients.
@Ronalfa is not being licensed at this time.
We're excited to release tcellMIL, an attention-based multiple instance learning model for predicting patient outcomes after CAR T cell therapy for lymphoma and nominating cell design strategies in #neurips2025 AI4D3! https://t.co/3WJBQmJ3W5
🧬 Excited to share Nicheformer out now in Nature Methods!
A transformer foundation model linking single-cell & spatial omics, learning spatial context from gene expression to map tissue organization.
Led by Ale Tejada & Anna Schaar 👏
👉 https://t.co/ba9DX7h2xg